Introduction
manner ( Figure 1A and B). A moderate decrease in pathological TGF-b overproduction was seen in rats Progressive accumulation of pathological extracellular treated with 10-20 mg of enalapril or 50-100 mg of matrix in the kidney is the main cause of end-stage losartan per litre of drinking water. With increasing renal disease in patients with hypertension, diabetes enalapril or losartan dose, a maximal reduction in mellitus or glomerulonephritis. Overexpression of the TGF-b overproduction was seen starting with 100 mg profibrotic cytokine transforming growth factor of enalapril or 500 mg of losartan in the drinking ( TGF )-b has been identified as key mediator of matrix water. A further increase in enalapril or losartan dose accumulation in a number of human and experimental did not decrease glomerular TGF-b production further. renal diseases [1] . In rats following induction of antiSide by side comparison of maximal effective doses of Thy1 glomerulonephritis, we used reduction in TGFenalapril or losartan showed a comparable reduction b overexpression as a novel target to evaluate several in TGF-b overexpression (enalapril −46%, losartan strategies to maximize the antifibrotic action of angio-−45%). Combined therapy with both modes of Ang tensin (Ang) II blockade [2] . We asked whether TGF-II blockade did not result in additional beneficial b expression can be reduced more effectively or even effects (−45%). In all experiments, changes in TGF-b normalized by increasing the doses of Ang II-blocking expression were closely correlated to the glomerular drugs or by combining angiotensin-converting enzyme matrix accumulation (r=0.96, P<0.001). No therapy (ACE) and angiotensin type 1 (AT1) receptor entirely normalized TGF-b and matrix protein antagonism.
overproduction.
Methods
Anti-Thy1 glomerulonephritis was induced in male Sprague-Dawley rats (225-280 g) fed a normal protein diet by the i.v. injection of OX-7 antibody (1.5 mg/kg). At 24 h after disease induction, rats were given the ACE inhibitor enalapril (0, 10-1000 mg/l, set 1) or the AT1 antagonist losartan (0, 50-2000 mg/l, set 2) in their drinking water. In set 3, rats were treated with enalapril (100 mg/l ), losartan (500 mg/l ) or a combination of both. The doses selected for enalapril and losartan had shown maximal efficacy in set 1 or 2. The animals were sacrificed 6 days after disease induction. Glomerular TGF-b1 synthesis was measured by enzyme-linked immunosorbent assay ( ELISA) in the supernatant of cultured glomeruli isolated from individual rats. Matrix accumulation was estimated using periodic acid-Schiff (PAS)-stained kidney tissue by a blinded observer.
Results

Fig. 1. Effect of Ang II blockade on glomerular TGF-b1 expression 6 days after induction of Anti-Thy1 glomerulonephritis (GN ). The
Following induction of anti-Thy1 glomerulonephritis, effect of increasing doses of (A) the ACE inhibitor enalapril and increasing doses of both enalapril and losartan reduced (B) the AT1 receptor blocker losartan in the drinking water. (C )
The effect of maximal effective doses of enalapril (Ena, 100 mg/l), losartan (Los, 500 mg/l ) or both (*P <0.01 vs GN ). Glomerular production of TGF-b1 served as an indicator of TGF-b1 expression Adenosine receptor antagonism in the prevention of acute cyclosporine A-nephrotoxicity in normal, diabetic and hypertensive rats
